Skin Substitution Products is the largest segment driving the growth of U.S. Acellular Dermal Matrices Market
The global U.S. Acellular Dermal Matrices Market is estimated to be valued at US$ 2783.32 Mn or Mn in 2023 and is expected to exhibit a CAGR of 3.8% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
SWOT Analysis
· Strength: Acellular dermal matrices offer effective tissue reinforcement and reduce postoperative hernia recurrence rates. They help integrate well with the native tissue.
· Weakness: High costs associated with acellular dermal matrices can limit their adoption.
· Opportunity: Growing geriatric population prone to hernias creates growth opportunities. Increasing awareness about benefits of acellular dermal matrices also presents opportunities.
· Threats: Stringent regulatory approvals and recalls of dermal matrix products pose threats. Reimbursement issues also restrict market growth.
Key Takeaways:-
The U.S. Acellular Dermal Matrices Market Size was valued at US$ 2783.32 Mn in 2023 and is expanding at a CAGR of 3.8% during the forecast period.
The rising incidence of hernias coupled with the growing geriatric population in the U.S. is a major factor driving the demand for acellular dermal matrices in the country. According to the National Center for Biotechnology Information (NCBI), groin hernias account for 75% of all hernias in the U.S., with over 1 million repairs done every year.
Regionally, the South region dominated the U.S. acellular dermal matrices market in 2023 and is expected to continue its dominance over the forecast period. This is attributed to the presence of major market players andavailability of advanced healthcare facilities in states such as Florida, Texas and North Carolina.
Key players operating in the U.S. Acellular Dermal Matrices market are Integra LifeSciences Corporation, AbbVie Inc., Johnson & Johnson, HansBioMed, Becton, Dickinson and Company, Cook Group, Smith & Nephew Plc., Reprise Biomedical, Organogenesis Holdings Inc., Tissue Regenix, LifeNet Health, Zimmer Biomet Holdings, Inc., Stryker Corporation, MiMedx Group, PolyNovo Limited, Fidia Pharma USA Inc., Baxter International Inc., In2Bones Global, BioHorizons, Inc., Harbor MedTech, Inc., MLM Biologics Inc., Geistlich Pharma AG, Olaregen Therix, Inc., EnColl Corporation, Kerecis limited, DSM, ACell Inc., 3M, Cell Constructs I, LLC, Marine Polymer Technologies, Inc.
English
Arabic
Français
Español
Português
Deutsch
Türkçe
Italiano
Russian
Romaian